Third Rock-backed startup's blood test can sniff out cancer in patients with no history of disease
The myriad of liquid biopsy companies working on blood tests for early cancer detection have been conducting retrospective studies, looking at how effective and sensitive their technology is in spotting cancer in patients that have already been diagnosed. Now, a Third Rock Ventures-backed startup has also shown its blood test can perform in a large prospective study involving patients with no personal history of cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.